This funding program — an Edmond J. Safra Core Program for PD Research — seeks to build conclusive evidence and develop field-enabling tools around early-stage biological targets in Parkinson’s disease (PD).
Funding will support projects to validate early-stage targets previously implicated in PD pathophysiology and/or symptomology but that have not yet been rigorously investigated for their ability to impact disease-relevant outcomes in PD model systems. Replication studies are encouraged to build data that could increase confidence in starting therapeutic translational programs. Studies may request access to MJFF-sponsored biospecimen and cell line collections.
For targets that are lacking pre-clinical tools and/or models, the Tool Generation track provides funding for the development of such resources to assist with the validation of the selected target. Please note, tools resulting from this funded work must be deposited in an MJFF-designated repository for community access after completion of the project.
We will not consider proposals focused on validation of established targets (alpha-synuclein, LRRK2, GBA, PRKN and PINK1) or proposing discovery studies to identify new targets.
Researchers from public and private institutions are encouraged to apply and to collaborate.
We will host a webinar on August 24, 2021, at 12 p.m. ET to clarify and explain the goals of our funding opportunities and answer applicant questions. The webinar will be available to view on-demand after the live airdate. Register today.
Email email@example.com with questions.